Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Jak/Stat Pathway

Chemical Structure Cat. No. Product Name CAS No.
GDC-0214 Chemical Structure
BCP47996 GDC-0214 1831144-46-7
GDC0214 is a potent, selective inhalable and lung-restricted inhibitor of JAK1 with IC50 of 8.52 nM, displays 6.3/704/28 fold selectivity over JAK2/JAK3/TYK2.
JAK-IN-5 hydrochloride Chemical Structure
BCP48031 JAK-IN-5 hydrochloride 2751323-21-2
JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
Stafia-1 Chemical Structure
BCP45558 Stafia-1 2582757-90-0
Stafia-1 is a the first potent and selective STAT5a inhibitor, displaying high selectivity over STAT5b and other STAT family members.
SJ10542 Chemical Structure
BCP46974 SJ10542 SJ10542
SJ10542 is JAK2/3 PROTAC. SJ10542 displayed high selectivity over GSPT1 and other members of the JAK family and potency in patient-derived ALL cells containing both JAK2 fusions and CRLF2 rearrangements.
FLLL31 Chemical Structure
BCP46782 FLLL31 52328-97-9
FLLL31, derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.
G5-7 Chemical Structure
BCP46781 G5-7 939681-36-4
G5-7 is an orally active JAK2 inhibitor, selectively inhibits JAK2-mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study.
SC99 Chemical Structure
BCP46780 SC99 882290-02-0
SC99 is a selective inhibitor of JAK2-STAT3 activation.
RSVA 405 Chemical Structure
BCP46773 RSVA 405 140405-36-3
RSVA-405 is a potent STAT3 inhibitor and is an analog of resveratol.
Sunvozertinib Chemical Structure
BCP46584 Sunvozertinib 2370013-12-8
Sunvozertinib, also known as DZD9008, is an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor. Sunvozertinib shows activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily.
L002 Chemical Structure
BCP46453 L002 321695-57-2
L-002 is an inhibitor of p300 histone acyltransferase (KAT3B). L-002 also inhibits acetylation of histones and p53 and suppresses STAT3 activation. In vivo, L-002 potently suppressed tumor growth of TNBC cell line MDA-MB-468 xenografts.
123下一页末页共 283 条记录 1 / 29 页 
0086-13720134139